Close
Smartlab Europe
Inizio Ignite

Drug Research

A collaborative approach to innovation in Pharma

“IGNITE is a creative environment that fosters innovative thinking and encourages new ideas and enables users to have their voice heard in overcoming challenges that are faced to find new ways to better deliver quality data, speed up clinical...

Niche CDMO adds spray drying for highly potent drugs

IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few contract development and manufacturing organisations (CDMO) to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB. ...

Roche’s Tecentriq shows positive results for lung-cancer treatment

Roche Holding AG (ROG.EB) said that a phase 3 IMpower150 study showed an improvement in the treatment of advanced lung cancer with the use of Tecentriq. The study showed that patients with advanced lung cancer live...

Johnson & Johnson Human Performance Institute Invests $18 Million for future of Lake Nona Medical City

The Johnson & Johnson Human Performance Institute today announced it is expanding its footprint in the Lake Nona community in Orlando, Florida with the construction of its new global headquarters. The $18 million state-of-the-art campus, located...

ADC Bio developing downstream bioconjugation process

ADC Biotechnology (ADC Bio) announces that it is developing a revolutionary, ‘downstream bioconjugation’ method that will present a new paradigm in Antibody Drug Conjugate (ADC) development and manufacturing. In contrast to the existing approaches – which...

Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration...

Inovio, Parker Institute for Cancer Immunotherapy enter clinical collaboration to evaluate new cancer immunotherapy combinations

Inovio Pharmaceuticals, Inc. and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that provides for Inovio and the Parker Institute to undertake clinical evaluation of novel combination regimens within the field of immuno-oncology. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »